[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@RNAiAnalyst Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::409194010.png) @RNAiAnalyst Dirk Haussecker

Sarepta Therapeutics ($SRPT) has received positive news regarding its gene therapy, Elevidys, as the FDA has lifted a hold on the treatment. The company's subcutaneous delivery of a Huntington's disease candidate has shown impressive results, although it does not target exon X. Additionally, Sarepta's partnership with Arrowhead Pharmaceuticals ($ARWR) may be renegotiated following the recent news.

### Engagements: XXXXX [#](/creator/twitter::409194010/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::409194010/c:line/m:interactions.svg)

- X Week XXXXXXX -XXXX%
- X Month XXXXXXX +83%
- X Months XXXXXXXXX +70%
- X Year XXXXXXXXX +3.50%

### Mentions: XX [#](/creator/twitter::409194010/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::409194010/c:line/m:posts_active.svg)

- X Week XX -XXXX%
- X Month XXX +42%
- X Months XXX +32%
- X Year XXXXX +28%

### Followers: XXXXXX [#](/creator/twitter::409194010/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::409194010/c:line/m:followers.svg)

- X Week XXXXXX +0.36%
- X Month XXXXXX +2.40%
- X Months XXXXXX +8.50%
- X Year XXXXXX +11%

### CreatorRank: XXXXXXX [#](/creator/twitter::409194010/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::409194010/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::409194010/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXX% [finance](/list/finance)  XXX% [cryptocurrencies](/list/cryptocurrencies)  XXXX% [countries](/list/countries)  XXXX%

**Social topic influence**
[$srpt](/topic/$srpt) #4, [$qure](/topic/$qure) #19, [$alny](/topic/$alny) #3, [$rna](/topic/$rna) #3, [$pepg](/topic/$pepg) #2, [$ntla](/topic/$ntla) #12, [$ions](/topic/$ions) #2, [$dyn](/topic/$dyn) #1, [$sln](/topic/$sln) #3, [$arwr](/topic/$arwr) #9

**Top accounts mentioned or mentioned by**
[@geneinvesting](/creator/undefined) [@grok](/creator/undefined) [@bambossie81](/creator/undefined) [@djtblows69](/creator/undefined) [@hall8jack](/creator/undefined) [@drmakaryfda](/creator/undefined) [@adamfeuerstein](/creator/undefined) [@towiu2](/creator/undefined) [@jfais20](/creator/undefined) [@hulksmash8181](/creator/undefined) [@john_hersc79276](/creator/undefined) [@biopharmiq](/creator/undefined) [@zhaoweiasu](/creator/undefined) [@elilillyandco](/creator/undefined) [@jamesmclaw70633](/creator/undefined) [@pearlf](/creator/undefined) [@sonichedgefund](/creator/undefined) [@hannibalspeaks](/creator/undefined) [@alamentarius](/creator/undefined) [@usfda](/creator/undefined)

**Top assets mentioned**
[Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [uniQure N.V. (QURE)](/topic/$qure) [Alnylam Pharmaceuticals, Inc. (ALNY)](/topic/$alny) [Avidity Biosciences, Inc. Common Stock (RNA)](/topic/$rna) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) [Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/$dyn) [Smart Layer Network (SLN)](/topic/$sln) [Arrowhead Research Corporation (ARWR)](/topic/$arwr) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Akropolis (AKRO)](/topic/$akro) [Biogen Inc (BIIB)](/topic/$biib) [Scholar Rock Holding Corporation Common Stock (SRRK)](/topic/$srrk) [Vertex Protocol (VRTX)](/topic/$vrtx) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Merck & Co., Inc. (MRK)](/topic/$mrk) [PTC Therapeutics, Inc. (PTCT)](/topic/$ptct) [Novo-Nordisk (NVO)](/topic/$nvo) [Novavax Inc (NVAX)](/topic/$nvax) [Moderna Inc (MRNA)](/topic/$mrna) [MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)](/topic/$mltx) [Synthetify (SNY)](/topic/$sny) [Protagonist Therapeutics, Inc (PTGX)](/topic/$ptgx)
### Top Social Posts [#](/creator/twitter::409194010/posts)
---
Top posts by engagements in the last XX hours

"$10B.that is the combined market cap of major DM1 players $RNA $DYN and $PEPG; add to this $VRTX w/ a approach and stage similar to $PEPG. $RNA also prices in large FSHD opportunity. DM1 is one of the largest genetic disease categories larger than CF. Combined market cap could ultimately be $50B in 2029. There is also likely a succession of therapies coming onto market that improve on earlier approved drugs: 1) $RNA: most advanced evidence of fct improvements but probably least effective on molecular level (CASI) 2) $DYN: a year behind $RNA but CASI superior and impressive fct data at WMS25"  
[X Link](https://x.com/RNAiAnalyst/status/1978743257090642124) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-16T08:42Z 20.5K followers, 4746 engagements


"Prediction: $ALNY will acquire RNAi player $RNA. DM1 is a similar-sized opportunity with ATTR-CM. $alny can make case of developing next-gen DM1 and FSHD medicines plus new muscle franchise"  
[X Link](https://x.com/RNAiAnalyst/status/1978841255783063872) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-16T15:11Z 20.5K followers, 5887 engagements


"$SLN may be the first RNAi casualty due to competition from China. This Co has done X over last decade in terms of progressing their tech incl extrahepatic delivery as more+more partnering competition for Lpa complement etc emerges"  
[X Link](https://x.com/RNAiAnalyst/status/1961437276828839985) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-08-29T14:34Z 20.5K followers, 2385 engagements


"@GeneInvesting @zhaoweiasu @ArkadiBaudelair The larger issue with wtATTR-CM is proper diagnosis. You obviously dont want to spend $2M on a patient that does not have TTR-related issues. $alny and $bbio risking a backlash if current trends continue"  
[X Link](https://x.com/RNAiAnalyst/status/1969017654322065505) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-09-19T12:36Z 20.5K followers, XXX engagements


"$qure $pepg today we are seeing groundbreaking data for X of the most common severe monogenic diseases: Huntington's and myotonic dystrophy type X. A XXXX% splicing correction hints at a cure for muscle-related issues in DM1; for Huntington's exon 1-knockdown will ultimately be complemented by strategies to slow down triplett expansion"  
[X Link](https://x.com/RNAiAnalyst/status/1970963092935770452) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-09-24T21:26Z 20.5K followers, 11.2K engagements


"@_financeken @Vulpescap Beautiful dose response. For measuring splice correction n=6 is adequate. $pepg"  
[X Link](https://x.com/RNAiAnalyst/status/1970964530764415440) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-09-24T21:32Z 20.5K followers, XXX engagements


"Seems like all the #biotech M&A's get preannounced by the FT or WSJ on Sundays now. Suddenly regret that I was not more aggressive on $RNA in after-hours. My bids did not get filled at $47.8"  
[X Link](https://x.com/RNAiAnalyst/status/1974461816672817172) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-04T13:09Z 20.5K followers, 5598 engagements


"$qure always thought logical next-gen to AMT-130 is co-lowering of MSH3 (repeat expansion) + exon1HTT (toxicity) -- does new gene therapy about to start clin trials aimed at lowering MSH3 involve uniQure Another Q also for $clpt degenerates: how long is neurosurgery for AMT-130 at moment Tabrizi claims it is too long for AMT-130 to be widely used based on a personal anecdote. She says other AAV serotypes would lower that. Could that hint at non-uniQure efforts Finally looks like $ions also working on MSH3 lowering using oligos"  
[X Link](https://x.com/RNAiAnalyst/status/1974756285741510690) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-05T08:39Z 20.5K followers, 7077 engagements


"💪week: $RNA (also M&A rumors) $DYN (pin action+WMS) $PEPG $SRPT (WMS25). $qure AMT-130 data presentation"  
[X Link](https://x.com/RNAiAnalyst/status/1974756848688591306) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-05T08:41Z 20.5K followers, 4505 engagements


"$qure Seems that AMT-130 availability could be less than demand initially but I expect that in profit-driven healthcare system hospitals will recognize potential of $clpt-enabled procedures and invest accordingly. 'The most important part of the surgery length beyond people occupying an extremely rare intraoperative MRI scanner are the people who have to be in that room.'"  
[X Link](https://x.com/RNAiAnalyst/status/1974780770733490676) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-05T10:16Z 20.5K followers, 9376 engagements


"$dyne sometimes when you are at the conference u are last to see data release PR. Saw the DM1 data this morning and was impressed by continued improvements and CNS-related symptom benefits. $rna $pepg"  
[X Link](https://x.com/RNAiAnalyst/status/1975850170433818797) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-08T09:06Z 20.5K followers, 2763 engagements


"@JoseRestonVA What about the CVR Basically for free just have to tie up capital for a bit. Or are you concerned abt antitrust Could there also be a higher offer from $mrk $akro"  
[X Link](https://x.com/RNAiAnalyst/status/1976992142246760813) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-11T12:43Z 20.5K followers, XXX engagements


"$ntla believe the next major re-rating of stock occurs when commercial uptake shows patients/KOLs love that type of medicine"  
[X Link](https://x.com/RNAiAnalyst/status/1978197853127180461) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-14T20:34Z 20.5K followers, 5485 engagements


"$srpt adds $200M to cash balance in Q2 alone. Balance now at $850M"  
[X Link](https://x.com/RNAiAnalyst/status/1953189807431270865) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-08-06T20:21Z 20.5K followers, 38.9K engagements


"$srpt 2027 convertible debt burden down from $1.2B to $450M with remainder largerly deferred to 2030: Seems like bankruptcy a highly unlikely scenario now and full steam ahead with #RNAi pipeline. $arwr"  
[X Link](https://x.com/RNAiAnalyst/status/1958488907894661520) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-08-21T11:18Z 20.5K followers, 11.3K engagements


"$BIIB $IONS CRL issued for another SMA drug today high-dose nusinersen; and once again it is because of CMC"  
[X Link](https://x.com/RNAiAnalyst/status/1970590861407985885) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-09-23T20:47Z 20.5K followers, 5574 engagements


"$qure IMO the coming intrathecal RNAi competition need to show superiority to one-time AMT-130. Life-long progressive disease. $alny $arwr"  
[X Link](https://x.com/RNAiAnalyst/status/1971485227894833480) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-09-26T08:01Z 20.5K followers, 4055 engagements


"$rna for the boring biotech traders on this app this one could be for you. I don't see how this does not get acquired over next year. Their delivery tech is legit and trailblazing. Initially thought conjugating oligos to antibodies too clumsy.but they made it work. Just don't get chickened out when buyout rumor comes and goes"  
[X Link](https://x.com/RNAiAnalyst/status/1974197621230055839) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-03T19:39Z 20.5K followers, 5694 engagements


"$mgx if they continue to make hemophilia A their priority (I'd advise against) then aiming for BTD based on preclinical data should be their goal :). $sprb"  
[X Link](https://x.com/RNAiAnalyst/status/1975312710515777651) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-06T21:30Z 20.5K followers, 3487 engagements


"#SMA there is no apparent disadvantage from treating CNS only after intrathecal ASO (nusinersen) admin vs systemic small molecule (risdiplam). Very comprehensive analysis. $ions $biib $ptct"  
[X Link](https://x.com/RNAiAnalyst/status/1975870890593399051) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-08T10:28Z 20.5K followers, 2654 engagements


"Decision was last week @statnews reports this morning after new bullish Elevidys data out. Mmh. $srpt"  
[X Link](https://x.com/RNAiAnalyst/status/1975882188139950193) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-08T11:13Z 20.5K followers, 12.7K engagements


"@john_hersc79276 In a disease where progression is so variable from patient to patient unless you run a much larger trial propensity matching much more suitable than random placebo. Of course you could ask for such a trial but have patients wait another X years. $qure"  
[X Link](https://x.com/RNAiAnalyst/status/1976368769560871365) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-09T19:26Z 20.5K followers, XXX engagements


"$prqr I will jinx it but the only explanation for not hearing anything from the company would be M&A. Anything else would be reason for panic. Will have to see whether $nvo jas some leftovers in poxkets after today's $akro acquisition"  
[X Link](https://x.com/RNAiAnalyst/status/1976374585684787578) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-09T19:49Z 20.5K followers, 3717 engagements


"$WVE AATD was never the big money maker for Co. It validated the #RNAediting platform. For most applications XX% editing is plenty. Yet it sold off on $BEAM/repeat admin data when obesity and cardiovascular are the crown jewels. Forget about Huntington's and DMD"  
[X Link](https://x.com/RNAiAnalyst/status/1976390489084493907) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-09T20:53Z 20.5K followers, 3546 engagements


"$qure Sunday for first scientific AMT-130 pivotal trial presentation"  
[X Link](https://x.com/RNAiAnalyst/status/1976732939020124200) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-10T19:33Z 20.5K followers, 24.9K engagements


"$srpt convened an expert panel on enhancing safety of Elevdiys. Observations: in both cases of ALF liver enzymes first increased X weeks post dose death 11weeks post dose (predictable time-course). #bilirubin was not increased in both fatalities shortly after liver enzyme increases vs no such observations in the XX non-fatal ALIs No relationship with weight/dose but likely liver health (steatosis) and consumptive coagulopathy may ultimately cause of T cell-initiated fatal course. Recs: more sensitive monitoring of liver tox markers; TREAT at earliest sign of liver enzyme increase with"  
[X Link](https://x.com/RNAiAnalyst/status/1976972698564575558) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-11T11:26Z 20.6K followers, 16.8K engagements


"Incredible (and timely) summary on critical importance of EXON1 in #Huntington's disease by unsung heroine Gillian Bates: -- in mouse models XX% exon 1-only kd much more impactful on pathopysiology than XX% full-length kd and much more: $qure $ions $wve $srpt $arwr"  
[X Link](https://x.com/RNAiAnalyst/status/1977332395641581710) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-12T11:15Z 20.5K followers, 9886 engagements


"In addition to knocking down huntingtin exon X we need additional strategies aiming at lowering use of cryptic intron X polyA sites (e.g. promoting RNAPolII processivity; targeting polyA signals using oligos etc). $qure $arwr $ions $srpt $wve #Huntingtons"  
[X Link](https://x.com/RNAiAnalyst/status/1977333164075802645) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-12T11:18Z 20.5K followers, 2906 engagements


"50% huntingtin exon X kd better than XX% full-length. $qure"  
[X Link](https://x.com/RNAiAnalyst/status/1977401217828401476) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-12T15:49Z 20.6K followers, 10.2K engagements


"$qure amt-130 presentation about to conclude. Anything new biotwitter"  
[X Link](https://x.com/RNAiAnalyst/status/1977401994030510275) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-12T15:52Z 20.5K followers, 15.6K engagements


"$pepg stock is held almost exclusively by tutes e.g. RA Capital (32%) Point72 (8%); I seem to be the only tax-paying non-tute 😜. Regardless considering $RNA and $DYN market caps of $6B and $2B respectively would be unfair to see offering at anything less than $300M pre-money. $pepg should have announced data first then do an offering after full trading day. Maybe RA Capital wants to add more and that's why"  
[X Link](https://x.com/RNAiAnalyst/status/1970961941343715457) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-09-24T21:22Z 20.5K followers, 6366 engagements


"$srpt no sirolimus PROPHYLAXIS X of XX with acute liver injury. Sirolimus prophylaxis: zero of X. Proph well tolerated. Single center experience"  
[X Link](https://x.com/RNAiAnalyst/status/1975894253953004000) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-08T12:01Z 20.5K followers, 12.3K engagements


"$ntla $srpt cant see Adam's tweets but is he squealing yet Do his handlers need to up the retainer"  
[X Link](https://x.com/RNAiAnalyst/status/1975969912473649393) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-08T17:01Z 20.5K followers, 8466 engagements


"$srpt getting more and more bullish ahead of earnings: 1) no more deaths since ambulatory only 2) sirolimus as backup (will have to see whether prophylaxis or on-demand wins out) 3) current market would support a $srpt pipeline even without Elevidys"  
[X Link](https://x.com/RNAiAnalyst/status/1975989905487757494) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-08T18:21Z 20.5K followers, 11.7K engagements


"@richtrades100 Of course it is about color $srpt provide about current market dynamics plus progress on successfully implementing sirolimus"  
[X Link](https://x.com/RNAiAnalyst/status/1976218711997796448) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-09T09:30Z 20.5K followers, XXX engagements


"Most important slide. Note how soon bilirubin moves.quite different from non-fatal ALIs. Question for AAV aficionados: is there similar pattern in past cases of systemic AAV ALFs $srpt"  
[X Link](https://x.com/RNAiAnalyst/status/1977023845153624178) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-11T14:49Z 20.5K followers, 10.8K engagements


"@Zappitelli1 No way. I'd be terrified having a significant long position going into earnings. Sandy has strung along shareholders quarter after quarter.and he'll continue to do so likely with another highly dilutive financing. $sgmo"  
[X Link](https://x.com/RNAiAnalyst/status/1952791488343216314) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-08-05T17:59Z 20.5K followers, 1205 engagements


"$ALNY $REGN: The POWER of #genetic medicine illustrated: (complement C5) mono RNAi better than RNAi-mAb combo despite XX% vs XX% complement assay inhibition respectively for myasthenia gravis. -- why I also expect $NTLA's ATTR and HAE treatment to kick ass. $SLN"  
[X Link](https://x.com/RNAiAnalyst/status/1960333599183696078) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-08-26T13:28Z 20.5K followers, 6131 engagements


"$NTLA unlike vutrisiran mNIS+7 improves in majority of ATTR-PN patients after NTLA-2001 one time treatment. Another @NEJM publication in the bag. $alny"  
[X Link](https://x.com/RNAiAnalyst/status/1971219595408310791) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-09-25T14:25Z 20.5K followers, 3795 engagements


"$NTLA I believe the ATTR-PN phase X data will be even better than the one reported today mainly because p3 does not include patients that had progressed on $ALNY's RNAi agents before. As you can see they did worse than knockdown-naive subjects"  
[X Link](https://x.com/RNAiAnalyst/status/1971291795968622899) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-09-25T19:12Z 20.5K followers, 4229 engagements


"$ALNY presents potentially game-changing argument for why ATTR-CM patients should take a silencer and not a stabilizer. -- vutrisiran reduces gastrointestinal events REGARDLESS of 1) tafamidis (which does not reduce baseline gastro effects) and 2) mutant or wild-type ATTR-CM. This is a reminder that ATTR is a multi-system disease and stabilizers possibly only good for cardiomyopathy manifestations. Important readthrough to $BBIO and $NTLA"  
[X Link](https://x.com/RNAiAnalyst/status/1972721472612216934) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-09-29T17:53Z 20.5K followers, 10.5K engagements


"$alny doses 1st patient in 11k subject CVOT of biannual anti-hypertensive #angiotensinogen RNAi. Triggers $300M milestone from partner Roche"  
[X Link](https://x.com/RNAiAnalyst/status/1973354407413842255) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-01T11:48Z 20.5K followers, 3245 engagements


"$60B MC $alny's biz dev team needs to be summarily fired for not taking advantage of #CRISPR firesale prices not long ago. CRISPR $ntla will eat a lot of its market share in the not too distant future. What were they thinking"  
[X Link](https://x.com/RNAiAnalyst/status/1975988277321793649) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-08T18:14Z 20.5K followers, 4831 engagements


"@Hall8Jack Maybe one of the $clpt people on here should educate him on the delivery. The videos of the striatum getting precisely filled/saturated with drug are beautiful. $qure"  
[X Link](https://x.com/RNAiAnalyst/status/1976028252046332183) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-08T20:53Z 20.5K followers, XXX engagements


"Anybody knows whether 'Dear Leader' got an mRNA or the $nvax protein covid vax $bntx $mrna"  
[X Link](https://x.com/RNAiAnalyst/status/1976967600807834104) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-11T11:06Z 20.5K followers, 5744 engagements


"@anna51296106 $srpt is now studying sirolimus in non-ambulatory. My guess is that if safety positive then back on label h2 2026. $srpt"  
[X Link](https://x.com/RNAiAnalyst/status/1976986829141512425) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-11T12:22Z 20.5K followers, 1592 engagements


"$qure after the initial euphoria and acknowledging the credibility of KOL Tabrizi and Wild can sense a heated bull-bear battle bubbling up. Think $srpt Elevidys. There are vested interests that dont like AMT-130. I also predict that Adam F will become their spokesperson"  
[X Link](https://x.com/RNAiAnalyst/status/1977141339281313898) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-11T22:36Z 20.5K followers, 6645 engagements


"More success for locally delivered #AAV gene therapy. $qure $regn $alsen.pa $bntc"  
[X Link](https://x.com/RNAiAnalyst/status/1977439464655085702) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-12T18:21Z 20.5K followers, 9887 engagements


"This guy nailed it. FILL-FINISH.I remember @JMaraganore X decades ago stressing that work not done until fill-finish secured. The irony is that Askshay Vaishnaw went from $ALNY to $SRRK"  
[X Link](https://x.com/RNAiAnalyst/status/1977732814633087069) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-13T13:47Z 20.5K followers, 6461 engagements


"$srrk $regn smart resourceful traders probably have a list with upcoming PDUFAs for new formulations that rely on the Catalent site. Can I see this list Catalent insiders probably shorting all of them now"  
[X Link](https://x.com/RNAiAnalyst/status/1977780133915189686) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-13T16:55Z 20.5K followers, 6590 engagements


"$ntla this Biocryst acquisition of $atxs made my day. First claimimf that patients CLEARLY prefer oral for prophylaxis now saying 'sorry we lied to you: every X months and less often much better'. Clearly freaking out about the coming one-time cure. $bcrx"  
[X Link](https://x.com/RNAiAnalyst/status/1978103253142237254) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-14T14:19Z 20.5K followers, 7046 engagements


"$EDIT just read up on LDL-R upregulation data in NHP.90-98% LDL-c reduction WITH EASE. A program to watch"  
[X Link](https://x.com/RNAiAnalyst/status/1978442686387368189) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-15T12:47Z 20.5K followers, 21.1K engagements


"$abvx in presentation CEO commended team on keeping placebo response low (by limiting enrolment in certain geographies etc) pointing to other recent examples i.e. $mltx and $sny. We all know these'failed' drugs are all active; most of the game is about pbo response mgmt"  
[X Link](https://x.com/RNAiAnalyst/status/1978472361184927943) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-15T14:45Z 20.5K followers, 6686 engagements


"$akro $omer new CEO blessing a number of deals Next signature under $prqr deal"  
[X Link](https://x.com/RNAiAnalyst/status/1978473642833981816) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-15T14:50Z 20.5K followers, 3852 engagements


"Down-to-earth data-based discussion of $pepg's DM1 program safety and efficacy. $dyn $rna"  
[X Link](https://x.com/RNAiAnalyst/status/1978588482315378977) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-15T22:27Z 20.5K followers, 8591 engagements


"@GeneInvesting 100k in US/EU each. Highly underdiagnosed. Could be more. Partly trolling $ALNY but for their own good. I'm just an internet guy ;)"  
[X Link](https://x.com/RNAiAnalyst/status/1978843218553848051) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-16T15:19Z 20.5K followers, XXX engagements


"$mgx moving"  
[X Link](https://x.com/RNAiAnalyst/status/1978846540056711359) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-16T15:32Z 20.5K followers, 2734 engagements


"$mgx remember this pure-play CRISPR Co (partnered with $IONS) trades XX% BELOW CASH"  
[X Link](https://x.com/RNAiAnalyst/status/1978846977975525447) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-16T15:34Z 20.5K followers, 3835 engagements


"Worth noting that among the first CNPVs issued is an #AAV gene therapy DB-OTO. $REGN $SRPT"  
[X Link](https://x.com/RNAiAnalyst/status/1979100955590205821) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-17T08:23Z 20.5K followers, 7844 engagements


"@calvi_robe85532 What can $SLN do that $alny cannot It amazes me that over the last XX years they still seem stuck in GalNAc-liver RNAi while the competition has zoomed passed them"  
[X Link](https://x.com/RNAiAnalyst/status/1979186902889537864) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-17T14:05Z 20.5K followers, XXX engagements


"@AssafSaadon Next stop: earnings. Otherwise no (Elevidys) news is good news here. Will be interesting how $srpt time the clinical trial news"  
[X Link](https://x.com/RNAiAnalyst/status/1979197326607384802) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-17T14:46Z 20.5K followers, XXX engagements


"$nktr these bitter legal fights NEVER end with an acquisition never. Wondering how many billions the betaville rumor mill has made from gullible retail"  
[X Link](https://x.com/RNAiAnalyst/status/1979258342422770150) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-17T18:48Z 20.5K followers, 11.1K engagements


"@FidelisAurelius @calvi_robe85532 Maybe it ends up being superior to $PTGX drug not only dosing advantage. Competes with $ions' most closely. $sln"  
[X Link](https://x.com/RNAiAnalyst/status/1979277671889834220) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-17T20:05Z 20.5K followers, XXX engagements